In a pooled analysis of 52 randomized controlled trials from the Celecoxib Clinical Database (n = 51,048), the selective cyclo-oxygenase-2 inhibitor celecoxib was associated with a decreased risk of gastrointestinal events when compared with nonselective NSAIDs. The rate of confirmed clinically relevant upper and lower gastrointestinal events incidence was lower, and the time to incidence of such events longer, in the celecoxib group than in the nonselective NSAIDs group.